Healthcare Outlook
Heparin Market to Record an Impressive Growth Rate by 2026
Heparin is used to prevent or treat certain blood vessel, heart, and lung conditions. It is also used in blood transfusion, blood samplings during prophylaxis treatment, and for treatment of blood clotting disorders Heparin may be used to diagnose and treat a serious blood condition called disseminated intravascular coagulation. Heparin is sometimes used alone or in combination with aspirin to prevent pregnancy loss and other problems.
The global heparin market size was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).
Request a Sample of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2602
Increasing incidences of coronary heart disease, pulmonary embolism, and deep vein thrombosis is expected to drive growth of the heparin market
Heparin is widely used clinically for dialysis, deep vein thrombosis (DVT) treatment, and most cardiac surgeries. It is also used to prevent blood clotting during open-heart surgery, kidney dialysis, bypass surgery, and blood transfusions. Kidney dialysis procedure is increasing with rising chronic kidney disease, worldwide. For instance, according to Kidney Care UK 2016 report, about 3 million people in the U.K. are suffering from chronic kidney disease (CKD).
Furthermore, increasing number of surgeries and rising prevalence of diseases such as deep vein thrombosis and coronary heart disease, are fueling demand for heparin, eventually driving growth of the heparin market, during the forecast period. According to the American Heart Association 2018 report, coronary heart disease accounts for 1 in 7 deaths in the U.S., killing over 366,800 people every year. As per the same source, the overall prevalence for myocardial infarction (MI) in the U.S. is about 7.9 million, or 3 percent in U.S. adults.
Heparin Market - Regional Insights
On the basis of region, the global heparin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe heparin market is expected to generate significant revenue share during the forecast period, owing to growing geriatric population and rising prevalence of long-term survivors of acute myocardial infarction (AMI). Survivors of AMI are at high risk of a recurrent myocardial infarction, as well as other manifestations of cardiovascular disease such as stroke. According to Lancet journal, 2017 report, acute myocardial infarction is the leading cause of hospital admissions and mortality in the UK and across the world.
Heparin Market - Competitive Landscape
Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
Detailed Segmentation:
Global Heparin Market, By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
Global Heparin Market, By Dosage Form:
Injection
Solutions
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/heparin-market-2602
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
